<DOC>
	<DOCNO>NCT02673476</DOCNO>
	<brief_summary>This study see effective safe ALS-008176 treating adult hospital Respiratory Syncytial Virus-Related Illness .</brief_summary>
	<brief_title>A Phase 2a Study Evaluate Orally Administered ALS-008176 Adults Hospitalized With Respiratory Syncytial Virus</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>1 . Subject ≥50 year age . 2 . Female subject nonchildbearing potential ( i.e. , surgically sterilize , postmenopausal [ amenorrhea 1 year confirm negative hormone panel ] ) also negative pregnancy test screening . 3 . Male subject must either surgically sterilize ( e.g. , postvasectomy orchiectomy ) willing adhere study 's contraceptive requirement . Male subjects'female partner ( ) must surgically sterilize postmenopausal ( amenorrhea 1 year ) female partner ( ) childbearing potential must willing able adhere contraceptive requirement . 4 . Each subject legal guardian must sign informed consent form ( ICF ) indicate understands purpose procedure require study willing participate study start screen activity . 5 . Subject positive RTPCR test result RSV time screen . NOTE : Coinfection acute virus bacteria permit . 6 . Subject , , admit hospital acute respiratory illness sign symptoms consistent viral infection ( e.g. , fever , cough , nasal congestion , runny nose , sore throat , myalgia , lethargy , shortness breath , wheeze ) onset &lt; 7 day anticipate time randomization . 1 . Subject undergoing peritoneal dialysis , hemodialysis hemofiltration estimate glomerular filtration rate ( GFR , determine CockcroftGault Formula ) &lt; 30 mL/min . 2 . Subject presence concurrent illness , include laboratory , vital sign , ECG , physical exam finding , medical history , opinion investigator , would place subject unreasonably increase risk result participation study . 3 . Subject report receive investigational drug vaccine within 30 day , 5 halflives ( whichever longer ) prior plan first dose study drug . 4 . Subject known history human immunodeficiency virus ( HIV ) chronic , active hepatitis infection . 5 . ALT &gt; 3×ULN AND bilirubin &gt; 2×ULN ( direct &gt; 35 % ) OR ALT &gt; 5×ULN 6 . Subjects hospitalize &gt; 72 hour time randomization . 7 . Subjects anticipate hospitalize &lt; 24 hour randomization . 8 . Subjects expect survive &lt; 48 hour . 9 . Recent ( &lt; 5 halflives ) use , anticipate use conduct study , concomitant medication ( prescription nonprescription ) inhibitor OAT3 transporter . 10 . Treatment current illness drug specifically target RSV infection ( e.g. , RSV immunoglobulin , ribavirin , palivizumab ) . Medications treat sequela RSV infection concurrent illness permit otherwise exclude . 11 . Subjects unwilling undergo regular nasal swab procedure physical abnormality limit ability collect regular nasal specimen . 12 . Subjects consider investigator immunocompromised past 12 month , whether due underlie medical condition medical therapy . 13 . Subjects unable take medication enterally ( e.g. , orally via nasogastric PEG tube ) know gastrointestinalrelated condition may interfere study drug absorption . 14 . Female subject pregnant breastfeeding 15 . In investigator 's opinion , subject unwilling unable comply protocol requirement , instruction , protocol state restriction , unlikely complete study plan . 16 . Subject know suspected hypersensitivity study drug excipients ( microcrystalline cellulose , mannitol , croscarmellose sodium , magnesium stearate , polyethylene glycol , polyvinyl alcohol , talc , titanium dioxide ) .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>